Dongyin shares renamed Luo Xin Pharmaceuticals Star Pharmaceutical Enterprise Huanxin release of industrial benefits

Medical Network May 15 hearing the evening of May 11, East sound of shares (002 793) announced that the company changed from May 12 The ticker symbol is "Elohim medicine." This also means that Shandong Elohim Pharmaceutical Group Co., Ltdshares backdoor reorganization east sound smooth ending, Elohim Pharmaceutical A shares officially entered the capital marketreason for the company's stock short changed, the East sounds shares, said the company in 2019 the implementation of major assets and issue shares to buy assets matters, after the transaction is completed, the company's main business major change, the transition into the pharmaceutical manufacturing industry, the main business of pharmaceutical product development, production and sale of the securities referred to change the company's existing core business matches, more in line with the company's actual situation2019 Nian 12 27, East sound of shares ( "Luoxin" was renamed before the securities referred to) release "issued shares to buy assets report ( draft) "(revised version)According to the revised draft after draft, east sound of shares and trading partner to sign the "profit compensation agreement" shows that performance commitment undertakes to implement this major asset restructuring is completed, the annual net Elohim Pharmaceutical in 2019, 2020 and 2021 annual annual implementation profit of not less than 550 million yuan, 650 million yuan and 750 million yuan, net profit for the deduction related to non-audited net profit owned by the parentthis year April 27, 2019 Annual Report Elohim Pharmaceutical disclosure, the company achieved operating income of 7.589 billion yuan, an increase of 22.18% over last year; net profit attributable to shareholders of listed companies 634 million yuan, an increase of 23.74% over last year; net profit excluding non-recurring gains and losses attributable to shareholders of listed companies was 5.62 billion yuan, up 39.86 percent over last yearDeduction from non-normalized mother Elohim Pharmaceutical net profit in 2019 to achieve 562 million yuan of view, the company has surpassed 2019 performance commitmentFurthermore, strong demand for rigidity pharmaceutical industry, by digestive system drugs, respiratory system drugs like class field for many years Plow Luoxin has formed a strong core competitiveness, and company the main products are in their therapeutic areas mainstream product, the higher the proportion of specific market share, ranking the market, compared with similar products with the industry clear competitive advantage, the situation is highly competitive or alternative does not exist, profitability steadilyAfter years of development, it has formed a set of Elohim Pharmaceuticaldevelopment, production, sales and service of medicalas one large group, the company in focus At the same time the advantages of the product is also actively cooperating with the world's leading healthcare companies, we are committed to creating a large health platform, and further enhance the company's appreciation of space through innovative research and developmentinnovation and R & D strength decisionAccording to the report data show that the year 2019, a total of Elohim Pharmaceutical R & D funds invested 486 million yuan, effectively supporting the company's research and development projects and innovation developmentby taking independent research and cooperation in research and development mode of combining, Elohim Pharmaceutical active distribution of innovative research and development to upgrade, focusing digestion, much-needed clinical drug development in the field of anti-tumor, innovative drug pipeline currently already has ten varieties, not only focusing digestive, respiratory, medicines urgently needed in the field of clinical anti-tumor, more aggressive layout upgrade research and development, a number of other self-developed varieties have also made substantial progresswherein, ATP competitive mTORC1 / mTORC2 selective inhibitors LXI-15029, selective estrogen receptor toner LX-039, PI3Kα selective inhibitors have entered clinical LX-086 1 research stage, potassium competitive acid blocker LXI-15028 and achieved the primary efficacy endpoint in three clinical studies; moreover LXI-15028, LXI-15029 two research pipeline of innovative drugs are included in the national "Key New drug creation" major science and technology programscompanies are constantly working to accelerate the development and evaluation of new generic drugs consistency of generic drugsAccording to announcements, in early 2020, after Elohim Pharmaceutical's Simvastatin Tablets (10mg, 20mg) is approved, a total of six drugs by conformance assessment, simvastatin is Following the captopril tablets (25mg) , the second paragraph of products for the cardiovascular therapeutic area in the window period is now rapidly developing international innovative drugs industry, not only in the country to speed up the Elohim Pharmaceutical R & D progress, but also by actively carry out international cooperation and development, pioneering and innovative ways to seize the global pharmaceutical innovation the commanding heights of the market Up to now, the company has with South Korea CJHealthCareCorporation, United States BauschHealthCompaniesInc., Aurobindo Pharma Limited (AurobindoPharma), AstraZeneca, France YSLAB, the world's leading pharmaceutical companies such as Teikoku Seiyaku deeper cooperation, continuously layout high technology barriers preparation products worth mentioning that, through the upstream forward-looking layout raw material production, Luoxin has a complete chain from raw materials to the formulation of the drug Investment and construction company pharmaceutical intermediates and bulk drugs factory has been established sterile chemical raw materials production system, anti-tumor pharmaceutical raw materials and other production systems In addition, the company started the construction of approximately 970 acres of raw material medicine industrial park, while reducing the cost of its own product formulations, enhance their overall competitive strength in the pharmaceutical industry chain, providing basic security in the layout of the international market for the Elohim Pharmaceutical .